| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Nov 12, 2018 | PRGO Perrigo Co Plc | Parker Geoffrey M.46 | Director | Buy | 3,000 | $65.35 | $196,058.10 | +120.0% | |
| Nov 12, 2018 | PCRX Pacira Biosciences, Inc. | Wicki Andreas71 | Director | Sell | 5,478 | $49.83 | $272,980.24 | -0.5% | |
| Nov 12, 2018 | SIGA Siga Technologies Inc | Savas Paul G | Director | Buy | 10,000 | $5.01 | $50,100.00 | +4.5% | |
| Nov 12, 2018 | AMRN Amarin Corp Plc\uk | Thero John F | President And CEO | Sell | 607,611 | $19.07 | $11,587,896.18 | -6.3% | |
| Nov 12, 2018 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 202,540 | $113.48 | $22,984,876.84 | - | |
| Nov 12, 2018 | SIGA Siga Technologies Inc | Gomez Phillip Louis III | Chief Executive Officer | Buy | 15,000 | $5.20 | $78,000.00 | New | |
| Nov 12, 2018 | AMPH Amphastar Pharmaceuticals, Inc. | Peters William J52 | CFO, SVP &Treasurer | Sell | 38,484 | $20.74 | $797,972.36 | -10.4% | |
| Nov 9, 2018 | PRGO Perrigo Co Plc | Kingma Todd W | Executive VP, General Counsel | Buy | 3,200 | $63.99 | $204,768.00 | +15.7% | |
| Nov 9, 2018 | PRGO Perrigo Co Plc | Andersen Svend47 | EVP &President Chci | Buy | 3,900 | $63.01 | $245,739.00 | +118.2% | |
| Nov 9, 2018 | IRWD Ironwood Pharmaceuticals Inc | Consylman Gina | Chief Financial Officer | Sell | 1,358 | $11.81 | $16,037.98 | -1.4% | |
| Nov 9, 2018 | PRGO Perrigo Co Plc | Kessler Murray S | CEO | Buy | 15,683 | $63.79 | $1,000,373.49 | +116.9% | |
| Nov 9, 2018 | TXMD Therapeuticsmd, Inc. | Bernick Brian | Director | Sell | 182,800 | $4.88 | $891,332.80 | -1.4% | |
| Nov 9, 2018 | PCRX Pacira Biosciences, Inc. | Wicki Andreas71 | Director | Sell | 58,245 | $51.11 | $2,977,090.72 | -2.7% | |
| Nov 9, 2018 | AMPH Amphastar Pharmaceuticals, Inc. | Zhou Rong59 | EVP, Production Center | Sell | 2,173 | $20.50 | $44,549.00 | -2.0% | |
| Nov 9, 2018 | AMPH Amphastar Pharmaceuticals, Inc. | Liawatidewi Yakob47 | SVP Corp Admin Center | Sell | 17,808 | $20.97 | $373,420.52 | -18.3% | |
| Nov 9, 2018 | AMPH Amphastar Pharmaceuticals, Inc. | Shandell Jason B. | President And General Counsel | Sell | 52,296 | $20.77 | $1,086,420.05 | -11.6% | |
| Nov 8, 2018 | JNJ Johnson & Johnson | Kapusta Ronald A | Controller, CAO | Sell | 8,441 | $145.15 | $1,225,200.18 | -32.8% | |
| Nov 8, 2018 | MRK Merck & Co., Inc. | Perlmutter Roger M | Exe V-p &Pres, Mrl | Sell | 225,443 | $75.27 | $16,967,967.40 | -61.4% | |
| Nov 8, 2018 | NBIX Neurocrine Biosciences Inc | Bozigian Haig P. | Chief Development Officer | Sell | 36,295 | $110.00 | $3,992,450.00 | -11.8% | |
| Nov 8, 2018 | BCRX Biocryst Pharmaceuticals Inc | Staab Thomas R II | Senior Vice President And CFO | Sell | 14,087 | $8.12 | $114,386.77 | -3.3% | |
| Nov 8, 2018 | BCRX Biocryst Pharmaceuticals Inc | Powell Lynne | Senior VP - CCO | Sell | 5,580 | $8.14 | $45,432.00 | -24.5% | |
| Nov 7, 2018 | EBS Emergent Biosolutions Inc. | Zoon Kathryn C62 | Director | Sell | 4,242 | $69.74 | $295,855.65 | -9.8% | |
| Nov 7, 2018 | JNJ Johnson & Johnson | Duato Joaquin | Vice Chair, Exec Committee | Sell | 40,000 | $144.36 | $5,774,480.00 | -30.0% | |
| Nov 7, 2018 | MRK Merck & Co., Inc. | Gerberding Julie L. | EVP Strat Comm, Gl Pub Policy | Sell | 36,218 | $75.14 | $2,721,348.08 | -43.9% | |
| Nov 7, 2018 | PCRX Pacira Biosciences, Inc. | Pace Gary W66 | Director | Buy | 4,000 | $51.29 | $205,160.00 | +16.4% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.